SAN FRANCISCO--(BUSINESS WIRE)--SmithRx, a next-generation pharmacy benefits management (PBM) company, closed a $60M Series C financing round — building on the company’s $20M Series B round raised in 2022. Led by top Silicon Valley healthcare venture capital firm Venrock, the latest funding positions SmithRx to continue reducing costs of pharmacy benefits for small and midsize self-insured businesses..

旧金山--（商业新闻短讯）--下一代药房福利管理（PBM）公司SmithRx在2022年筹集2000万美元的B轮融资基础上，完成了6000万美元的C轮融资。在硅谷顶级医疗保健风险投资公司Venrock的带领下，最新的资金支持SmithRx继续降低中小型自保企业的药房福利成本。。

“Medications in the U.S. cost too much because the overall system is broken,” said Jake Frenz, founder and CEO of SmithRx. “At the core of this broken system are pharmacy benefit managers that drive up the costs. As a result, Americans can’t afford the drugs they need. The SmithRx model provides access to lifesaving and innovative drugs at low cost to patients.

SmithRx的创始人兼首席执行官杰克·弗伦茨（JakeFrenz）说：“美国的药物价格太高，因为整个系统都坏了。”。“这个破碎系统的核心是药房福利管理人员，他们推高了成本。因此，美国人买不起他们需要的药物。SmithRx模式为患者提供了低成本的救生和创新药物。

We use technology to simplify and create a viable path forward for plan sponsor clients, patients, brokers, and manufacturers.”.

我们利用技术简化并为计划赞助商客户、患者、经纪人和制造商创造可行的前进道路。”。

SmithRx continues to deliver on its commitment to paradigm-shifting cost savings through innovative programs like Autoimmune Savings and Low-Cost Insulin and partnerships with Mark Cuban Cost Plus Drug Company and Amazon Pharmacy among others.

SmithRx继续通过创新项目（如自身免疫节约和低成本胰岛素）以及与Mark Cuban cost Plus Drug Company和亚马逊药房等合作伙伴关系，履行其转变成本节约模式的承诺。

“Currently, the pharmacy sector ecosystem is riddled with, and frankly built on, misaligned incentives. As a result, costs are high and transparency is low. SmithRx’s radically aligned, and therefore unique, PBM platform ensures the best savings possible in the most transparent way for every employer, regardless of size,” said Bryan Roberts, a partner at Venrock..

“目前，制药行业的生态系统充满了不协调的激励机制，坦率地说，这些激励机制是建立在不协调的激励机制之上的。因此，成本很高，透明度很低。SmithRx的完全一致的、因此独特的PBM平台确保了每一个雇主，无论规模大小，都能以最透明的方式尽可能节省成本，”文洛克的合伙人布莱恩·罗伯茨（BryanRoberts）说。。

About SmithRx

关于SmithRx

SmithRx is working to reduce complexity and cost by building a new type of pharmacy benefits manager (PBM). Combining advanced technology, a member-centric approach, and innovative cost savings programs, we are making prescriptions more affordable and delivering valuable simplicity, transparency, and savings to main street businesses.

SmithRx正在通过建立一种新型的药房福利管理器（PBM）来降低复杂性和成本。结合先进技术、以会员为中心的方法和创新的成本节约计划，我们正在使处方更实惠，并为主要街道企业提供有价值的简单性、透明度和节约。

SmithRx is at the forefront of reshaping pharmacy benefits for small employers across the United States. Visit SmithRx.com..

SmithRx在为全美小型雇主重塑药房福利方面处于领先地位。访问SmithRx.com。。

About Venrock

关于Venrock

Originally established as the venture capital arm of the Rockefeller family in 1969, Venrock partners with entrepreneurs to build some of the world’s most disruptive, successful companies. With a primary focus on technology and healthcare, portfolio companies have included 10X Genomics, Apple Computer, AveXis, Check Point Software, CloudFlare, Gilead Sciences, Idec Pharma, Illumina, Intel, Millennium Pharma and Nest.

1969年，Venrock最初作为洛克菲勒家族的风险投资部门成立，与企业家合作建立了一些世界上最具破坏性、最成功的公司。投资组合公司主要专注于技术和医疗保健，包括10X Genomics、Apple Computer、AveXis、Check Point Software、CloudFlare、Gilead Sciences、Idec Pharma、Illumina、Intel、Millennium Pharma和Nest。

For more information, please visit Venrock’s website at www.venrock.com and follow the firm on X at @venrock..

欲了解更多信息，请访问Venrock的网站www.Venrock.com，并在X@Venrock上关注该公司。。